Abstract
We evaluated the safety and effectiveness of postdilating a 3.0 mm sirolimus-eluting stents (SESs; six cells) with a 3.5-4.0 mm balloon. We identified 254 consecutive patients who underwent percutaneous coronary interventions using SESs with a nominal diameter of 3.0 mm (six cells). Patients were divided into two groups based on whether they were subsequently postdilated with a 3.0 mm (group 1: 168 patients, 251 lesions) or a 3.5-4 mm balloon (group 2: 86 patients, 102 lesions). There were no significant differences regarding the incidence of in-hospital and long-term follow-up. Angiographic follow-up was available in 72% and 74% of groups 1 and 2, respectively. The two groups had no significant differences regarding late lumen loss (0.51 ± 0.36 vs. 0.52 ± 0.33; P = 0.3) and binary restenosis rates (10.7% vs. 8.8%; P = 0.1). Six-month clinical follow-up was available in all patients. At long-term follow-up (mean: 10.6 ± 3.7 for group 1 and 11.3 ± 3.9 months for group 2), there were no significant differences between the two groups regarding major adverse cardiac events (8.9% vs. 9.2%; P = 0.9). Implantation of a 3.0 mm SES with postdilation with a 3.5-4 mm balloon did not result in any significant difference in complications, in-hospital non-Q-wave myocardial infarction, binary restenosis, or target lesion revascularization. These data should lessen concern that overdilation may dilute the beneficial effects of SESs.
| Original language | English |
|---|---|
| Pages (from-to) | 129-133 |
| Number of pages | 5 |
| Journal | Catheterization and Cardiovascular Interventions |
| Volume | 64 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2005 |
Fingerprint
Keywords
- Drug-eluting stents
- Overdilatation
- Percutaneous coronary interventions
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Radiology Nuclear Medicine and imaging
Cite this
Is overdilatation of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate? / Iakovou, Ioannis; Stankovic, Goran; Montorfano, Matteo; Airoldi, Flavio; Chieffo, Alaide; Sangiorgi, Giuseppe M.; Carlino, Mauro; Corvaja, Nicola; Iassen, Michev; Rogacka, Renata; Vitrella, Giancarlo; Colombo, Antonio.
In: Catheterization and Cardiovascular Interventions, Vol. 64, No. 2, 02.2005, p. 129-133.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Is overdilatation of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate?
AU - Iakovou, Ioannis
AU - Stankovic, Goran
AU - Montorfano, Matteo
AU - Airoldi, Flavio
AU - Chieffo, Alaide
AU - Sangiorgi, Giuseppe M.
AU - Carlino, Mauro
AU - Corvaja, Nicola
AU - Iassen, Michev
AU - Rogacka, Renata
AU - Vitrella, Giancarlo
AU - Colombo, Antonio
PY - 2005/2
Y1 - 2005/2
N2 - We evaluated the safety and effectiveness of postdilating a 3.0 mm sirolimus-eluting stents (SESs; six cells) with a 3.5-4.0 mm balloon. We identified 254 consecutive patients who underwent percutaneous coronary interventions using SESs with a nominal diameter of 3.0 mm (six cells). Patients were divided into two groups based on whether they were subsequently postdilated with a 3.0 mm (group 1: 168 patients, 251 lesions) or a 3.5-4 mm balloon (group 2: 86 patients, 102 lesions). There were no significant differences regarding the incidence of in-hospital and long-term follow-up. Angiographic follow-up was available in 72% and 74% of groups 1 and 2, respectively. The two groups had no significant differences regarding late lumen loss (0.51 ± 0.36 vs. 0.52 ± 0.33; P = 0.3) and binary restenosis rates (10.7% vs. 8.8%; P = 0.1). Six-month clinical follow-up was available in all patients. At long-term follow-up (mean: 10.6 ± 3.7 for group 1 and 11.3 ± 3.9 months for group 2), there were no significant differences between the two groups regarding major adverse cardiac events (8.9% vs. 9.2%; P = 0.9). Implantation of a 3.0 mm SES with postdilation with a 3.5-4 mm balloon did not result in any significant difference in complications, in-hospital non-Q-wave myocardial infarction, binary restenosis, or target lesion revascularization. These data should lessen concern that overdilation may dilute the beneficial effects of SESs.
AB - We evaluated the safety and effectiveness of postdilating a 3.0 mm sirolimus-eluting stents (SESs; six cells) with a 3.5-4.0 mm balloon. We identified 254 consecutive patients who underwent percutaneous coronary interventions using SESs with a nominal diameter of 3.0 mm (six cells). Patients were divided into two groups based on whether they were subsequently postdilated with a 3.0 mm (group 1: 168 patients, 251 lesions) or a 3.5-4 mm balloon (group 2: 86 patients, 102 lesions). There were no significant differences regarding the incidence of in-hospital and long-term follow-up. Angiographic follow-up was available in 72% and 74% of groups 1 and 2, respectively. The two groups had no significant differences regarding late lumen loss (0.51 ± 0.36 vs. 0.52 ± 0.33; P = 0.3) and binary restenosis rates (10.7% vs. 8.8%; P = 0.1). Six-month clinical follow-up was available in all patients. At long-term follow-up (mean: 10.6 ± 3.7 for group 1 and 11.3 ± 3.9 months for group 2), there were no significant differences between the two groups regarding major adverse cardiac events (8.9% vs. 9.2%; P = 0.9). Implantation of a 3.0 mm SES with postdilation with a 3.5-4 mm balloon did not result in any significant difference in complications, in-hospital non-Q-wave myocardial infarction, binary restenosis, or target lesion revascularization. These data should lessen concern that overdilation may dilute the beneficial effects of SESs.
KW - Drug-eluting stents
KW - Overdilatation
KW - Percutaneous coronary interventions
UR - http://www.scopus.com/inward/record.url?scp=19944431246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19944431246&partnerID=8YFLogxK
U2 - 10.1002/ccd.20276
DO - 10.1002/ccd.20276
M3 - Article
VL - 64
SP - 129
EP - 133
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
SN - 1522-1946
IS - 2
ER -